UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/776,874	02/06/2001	Iris Pecker	01/21603	8407
Martin D. Moyi	7590 06/17/200 nihan	EXAMINER		
PRTSI, Inc.			HUTSON, RICHARD G	
P. O. Box 16446 Arlington, VA 22215			ART UNIT	PAPER NUMBER
			1652	
			MAIL DATE	DELIVERY MODE
			06/17/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)					
Office Action Comments	09/776,874	PECKER ET AL.					
Office Action Summary	Examiner	Art Unit					
	Richard G. Hutson	1652					
The MAILING DATE of this communication a Period for Reply	appears on the cover sheet with the	e correspondence address					
A SHORTENED STATUTORY PERIOD FOR REF WHICHEVER IS LONGER, FROM THE MAILING  - Extensions of time may be available under the provisions of 37 CFR after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory peri  - Failure to reply within the set or extended period for reply will, by sta Any reply received by the Office later than three months after the may earned patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUNICATION 1.136(a). In no event, however, may a reply be liod will apply and will expire SIX (6) MONTHS frouture, cause the application to become ABANDO	ON. timely filed om the mailing date of this communication. NED (35 U.S.C. § 133).					
Status							
1)⊠ Responsive to communication(s) filed on 13	8 March 2008						
	his action is non-final.						
<u>, _</u>	,—						
,—	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
ologod in decendance with the practice direct	7. Ex parte Quayre, 1000 C.D. 11,	100 0.0. 210.					
Disposition of Claims							
4)⊠ Claim(s) <u>127 and 129</u> is/are pending in the	application.						
4a) Of the above claim(s) is/are withd	4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.							
6)⊠ Claim(s) <u>127 and 129</u> is/are rejected.							
7) Claim(s) is/are objected to.							
8) Claim(s) are subject to restriction and	d/or election requirement.						
Application Papers							
9)☐ The specification is objected to by the Examiner.							
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).							
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.							
Priority under 35 U.S.C. § 119							
<ul> <li>12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some * c) None of:</li> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No</li> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>							
Attachment(s)  1) Notice of References Cited (PTO-892)  2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  3) Information Disclosure Statement(s) (PTO/SB/08)  Paper No(s)/Mail Date 4/2008.	4)  Interview Summa Paper No(s)/Mail 5)  Notice of Informa 6)  Other:						

Art Unit: 1652

## **DETAILED ACTION**

Applicant's amendment of the specification in the paper submitted on 3/13/2008 is acknowledged.

The finality of the previous action under Ex Parte Quayle is hereby withdrawn and following rejections are deemed to apply to claim 127 and 129.

## Claim Rejections - 35 USC § 101

35 U.S.C. 101 reads as follows:

Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.

Claim 129 is rejected under 35 U.S.C. § 101 because the claimed invention is directed toward non-statutory subject matter. In the absence of the hand of man, naturally proteins are considered non-statutory subject matter. Diamond v. Chakrabarty, 206 USPQ 193 (1980). This rejection may be overcome by amending the claims to contain wording such as "An isolated and purified heparanase protein ...".

## Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970);and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 127 and 129 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claim 1 of U.S. Patent No. 6,426,209 B1. An obvious type double patenting rejection is appropriate where conflicting claims are not identical, but an examined application claim is not patentably distinct from the reference claim(s) because the claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g.., *In re* Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re* Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re* Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985).

Although the conflicting claims are not identical, they are not patentably distinct from each other because claim 1 of U.S. Patent No. 6,426,209 B1, is drawn to a recombinantly made mammalian heparanase protein having an amino acid sequence at least 70% homologous to SEQ ID NO: 2. It is noted that SEQ ID NO: 2 of U.S. Patent No. 6,426,209 B1 and SEQ ID NO: 10 of the instant application are 100 % identical. U.S. Patent No. 6,426,209 B1 further discloses the claimed species of SEQ ID NO: 10 with an amino acid substitution of Tyr at position 246 to Phe.

Thus applicants claimed species is obvious over that genus claimed by U.S. Patent No. 6,426,209 B1 based upon the fact that U.S. Patent No. 6,426,209 B1also teaches the claimed species.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Richard G. Hutson whose telephone number is 571-272-0930. The examiner can normally be reached on M-F, 7:00-4:00.

Application/Control Number: 09/776,874 Page 4

Art Unit: 1652

273-8300.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Nashaat T. Nashed can be reached on 571-272-0934. The fax phone number for the organization where this application or proceeding is assigned is 571-

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

rgh 6/11/2008

/Richard G Hutson, Ph.D./ Primary Examiner, Art Unit 1652